Literature DB >> 26625219

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Jonathan D Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Carlton L Schwab, Diana P English, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Alessandro D Santin.   

Abstract

Entities:  

Year:  2015        PMID： 26625219      PMCID： PMC4705897          DOI： 10.1038/bjc.2015.388

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Correction to: British Journal of Cancer (2015) 113, 1020–1026; doi:10.1038/bjc.2015.306 It has been brought to our attention that there is an error in Figure 3 of the above paper published in advance online on 1 September 2015. The original label above the figure reads as ‘ARK-2 E93Q'. It should be corrected to ‘ARK-2 R93Q'.
  9 in total

1.  Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.

Authors:  Elena Bonazzoli; Stefania Bellone; Luca Zammataro; Barbara Gnutti; Adele Guglielmi; Silvia Pelligra; Nupur Nagarkatti; Paola Manara; Joan Tymon-Rosario; Burak Zeybek; Gary Altwerger; Gulden Menderes; Chanhee Han; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Vaagn Andikyan; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2020-06-26       Impact factor: 5.482

Review 2.  Prevalence and role of HER2 mutations in cancer.

Authors:  Emiliano Cocco; Salvatore Lopez; Alessandro D Santin; Maurizio Scaltriti
Journal:  Pharmacol Ther       Date:  2019-04-02       Impact factor: 12.310

3.  SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Authors:  Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

4.  Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.

Authors:  Emiliano Cocco; Salvatore Lopez; Jonathan Black; Stefania Bellone; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Carlton L Schwab; Gulden Menderes; Luca Zammataro; Natalia Buza; Pei Hui; Serena Wong; Siming Zhao; Yalai Bai; David L Rimm; Elena Ratner; Babak Litkouhi; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Br J Cancer       Date:  2016-06-28       Impact factor: 7.640

5.  Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.

Authors:  Daniel E Carvajal-Hausdorf; Kurt A Schalper; Yalai Bai; Jonathan Black; Alessandro D Santin; David L Rimm
Journal:  Gynecol Oncol       Date:  2017-02-11       Impact factor: 5.482

6.  BET inhibitors: Betting on improved outcomes in uterine serous carcinoma.

Authors:  Burak Zeybek; Salvatore Lopez; Alessandro D Santin
Journal:  Oncotarget       Date:  2018-10-26

7.  HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.

Authors:  Lisa Vermij; Nanda Horeweg; Alicia Leon-Castillo; Tessa A Rutten; Linda R Mileshkin; Helen J Mackay; Alexandra Leary; Melanie E Powell; Naveena Singh; Emma J Crosbie; Vincent T H B M Smit; Carien L Creutzberg; Tjalling Bosse
Journal:  Cancers (Basel)       Date:  2020-12-25       Impact factor: 6.639

8.  Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer.

Authors:  Michael D Toboni; Elena Lomonosova; Shaina F Bruce; Jo'an I Tankou; Mary M Mullen; Angela Schab; Alyssa Oplt; Hollie Noia; Danny Wilke; Lindsay M Kuroki; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; Dineo Khabele; David G Mutch; Katherine C Fuh
Journal:  Cancers (Basel)       Date:  2021-11-23       Impact factor: 6.639

Review 9.  Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.

Authors:  Britt K Erickson; Burak Zeybek; Alessandro D Santin; Amanda N Fader
Journal:  Curr Opin Obstet Gynecol       Date:  2020-02       Impact factor: 2.211
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.